RDGL VIVOS INC
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1449349 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY392.2%
TTM net income YoY-27.1%
TTM EPS YoY-100.0%
Revenue 3-yr CAGR69.3%
Net income 3-yr CAGR—
Margins
Gross margin6.8%
Operating margin-2,414.0%
Net margin-3,032.9%
FCF margin—
EBITDA margin—
Returns
ROE-180.2%
ROA-167.1%
ROIC (approx.)-2,040.3%
Asset turnover0.06x
Leverage & solvency
Liabilities / assets9.7%
Debt / equity0.00x
Current ratio12.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-66.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $68,379 | $27,995 |
| Cost of revenue | $128,134 | $30,979 |
| Gross profit | -$59,755 | -$2,984 |
| R&D expense | $352,232 | $324,629 |
| SG&A expense | $296,556 | $241,824 |
| Operating income | -$3.17M | -$2.60M |
| Pretax income | -$3.07M | -$2.91M |
| Net income | -$3.07M | -$2.91M |
| EBITDA | -$3.16M | — |
| EPS (basic) | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 452.72M | 409.67M |
| Banking | ||
| Net interest income | $99,030 | $74,936 |
| Balance sheet | ||
| Cash & equivalents | $1.56M | $2.21M |
| Receivables | $22,331 | $10,326 |
| Inventory | $57,257 | — |
| Current assets | $1.65M | $2.23M |
| PP&E, net | $102,811 | — |
| Total assets | $1.87M | $2.23M |
| Current liabilities | $117,892 | $86,209 |
| Total liabilities | $206,743 | $86,209 |
| Shareholders' equity | $1.66M | $2.15M |
| Shares outstanding | 455.49M | 440.87M |
| Cash flow statement | ||
| Operating cash flow | -$2.06M | -$1.68M |
| Capital expenditure | $103,185 | — |
| Free cash flow | -$2.16M | — |
| Investing cash flow | -$103,185 | — |
| Financing cash flow | $1.51M | $2.30M |
| Depreciation & amortization | $374 | — |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.